Response and remission after first-line corticosteroid therapy in primary immune thrombocytopenia
DOI:
https://doi.org/10.7196/Keywords:
Remission corticosteroids ITPAbstract
Background. Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterised by an isolated thrombocytopenia of <100 × 109/L in the absence of identifiable secondary causes. Treatment is indicated when the platelet count is <20 - 30 × 109/L, but may be commenced at higher platelet counts when the risk of bleeding is high. Corticosteroids are the backbone of initial treatment of ITP. There is a paucity of data in South Africa (SA) on the outcomes of newly diagnosed ITP patients treated with corticosteroids.
Objectives. To describe the response, remission and clinical outcomes of newly diagnosed primary ITP patients on first-line corticosteroids.
Methods. This was a retrospective cohort study of 68 patients with a new diagnosis of ITP, seen at the Clinical Haematology Unit at Groote Schuur Hospital, Cape Town, SA, over a 5-year period (2016 - 2020). Demographic and clinical data were obtained from paper and electronic record systems. All participants with secondary causes were excluded. The initial platelet responses to corticosteroids and the final outcomes at last follow-up were determined. Initial platelet responses were classified into no response (NR), partial response (PR) and complete response (CR) in accordance with consensus definitions. Remission was defined as maintenance of a CR after being off corticosteroids for ≤6 months. Categorical variables were described by frequencies and percentages, while numerical variables were described by medians and interquartile ranges (IQRs) as data were non-parametric.
Results. The majority of patients were female (88.2%) and the median (IQR) age at diagnosis was 36 (23.0 - 55.5) years. The female to male ratio was 7.5:1. Most (92.4%) patients responded to corticosteroids, with 74.2% achieving a CR and 18.2% achieving a PR. Only five patients failed to respond (7.6%). The median (IQR) time to achieve CR was 15 (8 - 25) days, and the median (IQR) time to achieve PR was 10.5 (8 - 22) days. Half of the patients went into remission. Following remission, two patients (6.1%) subsequently relapsed at day 344 and day 777, respectively. Hypertension and/or diabetes mellitus were newly diagnosed in 10.6% of patients.
Conclusion. Corticosteroids are effective first-line therapy for ITP, but are not remission-inducing in all patients. For those patients progressing to chronic ITP, there is a need to investigate cost-effective treatment. Some patients are at high risk of developing new hypertension and diabetes mellitus on corticosteroids, and should be monitored.
References
1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168-186. https://doi. org/10.1182/blood-2009-06-225565
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113(11):2386-2393. https://doi.org/10.1182/blood-2008-07-162503
3. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: A population-based study and literature review. Int J Hematol 2011;93(3):329-335. https://doi.org/10.1007/s12185-011-0791-1
4. Feudjo-Tepie MA, Hall S, Logie J, Bennett D. The incidence of idiopathic thrombocytopenic purpura (ITP) among adults in the United Kingdom’s General Practice Research Database (GPRD), 1992 - 2005. Blood 2007;110(11):3209. https://doi.org/10.1182/blood.V110.11.3209.3209
5. Frederiksen H, Christianse CF, Nørgaard M. Risk and prognosis of adult primary immune thrombocytopenia. Exp Rev Hematol 2012;5(2):219-228. https://doi.org/10.1586/ehm.12.7
6. Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol/ Hematol 2005;54(2):107-116. https://doi.org/10.1016/j.critrevonc.2004.12.004
7. Najean Y, Ardaillou N, Dresch C, Bernard J. The platelet destruction site in thrombocytopenic purpuras. Br J Haematol 1967;13(3):409-426. https://doi.org/10.1111/j.1365-2141.1967.tb08755.x
8. Piel-Julian M, Mahevas M, Germain J, et al. Risk factors for bleeding, including platelet count
threshold, in newly diagnosed ITP patients. Blood 2017;130(Suppl 1):S1041. https://doi.org/10.1111/
jth.14227
9. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3(23):3829-3866. https://doi.org/10.1182/ bloodadvances.2019000966
10. Woldeamanuel GG, Wondimu DH. Prevalence of thrombocytopenia before and after initiation of HAART among HIV infected patients at Black Lion Specialized Hospital, Addis Ababa, Ethiopia: Across sectional study. BMC Hematol 2018;18:9. https://doi.org/10.1186/s12878-018-0103-6
11. Opie J. Haematological complications of HIV infection. S Afr Med J 2012;102(6):465-468. https://doi. org/10.7196/samj.5595
12. Abdullah I, Subramony N, Musekwa E, et al. Indications and diagnostic value of bone marrow examination in HIV-positive individuals: A 3-year review at Tygerberg Hospital. S Afr J Infect Dis 2021;36(1):273. https://doi.org/10.4102%2Fsajid.v36i1.273
13. Stasi R, Newland AC. ITP: A historical perspective. Br J Haematol 2011;153(4):437-450. https://doi. org/10.1111/j.1365-2141.2010.08562.x
14. Salama A. Emerging drugs for immune thrombocytopenia. Exp Op Emerging Drugs 2017;22(1):27-38.
https://doi.org/10.1080/14728214.2017.1294158
15. Vianelli N, Valdrè L, Vivo A, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 2001;86(5):504-509.
16. Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: Results in 490 cases. Haematologica 1993;78(6 Suppl 2):S22-S28.
17. Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone
for previously untreated primary immune thrombocytopenia: A systematic review and meta-analysis.
Lancet Haematol 2016;3(10):e489-e496. https://doi.org/10.1016/s2352-3026(16)30109-0
18. Stanbury RM, Graham EM. Systemic corticosteroid therapy – side effects and their management.
Br J Ophthalmol 1998;82(6):704-708. https://doi.org/10.1136/bjo.82.6.704
19. Antel KR, Panieri E, Novitzky N. Role of splenectomy for immune thrombocytopenic purpura (ITP)
in the era of new second-line therapies and in the setting of a high prevalence of HIV-associated ITP. S Afr Med J 2015;105(5):408-412. https://doi.org/10.7196/samj.8987
20. Abdulraheem TR. Impact of splenectomy on the management of immune thrombocytopenia in adults. MMed thesis. Johannesburg: University of the Witwatersrand, 2018:1-79.
21. Jacobs P, Wood L, Novitzky N. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: A prospective randomized clinical trial. Am J Med1994;97(1):55-59. https://doi.org/10.1016/0002-9343(94)90048-5
22. Jacobs P, Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis. Blut 1989;59(1):92-95. https://doi.org/10.1007/bf00320256 23. Variava F. Immune thrombocytopenia at Chris Hani Baragwanath Hospital. MMed thesis.
Johannesburg: University of the Witwatersrand, 2014:1-103.
24. Kurata Y, Miragawa S, Kosugi S, et al. Clinical significance of antinuclear antibody in patients with
idiopathic thrombocytopenic purpura. Rinsho Ketsueki 1992;33(9):1178-1182.
25. Aringer M, Johnson SR. Systemic lupus erythematosus classification and diagnosis. Rheum Dis Clin
North Am 2021;47(3):501-511. https://doi.org/10.1016/j.rdc.2021.04.011
26. Sirotich E, Guyat G, Gabe C, et al. Definition of a critical bleed in patients with immune
thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology.
J Thromb Haemostasis 2021;19(8):2082-2088. https://doi.org/10.1111/jth.15368
27. Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of iron deficiency in
pregnancy. Br J Haematol 2019;188(6):819-830. https://doi.org/10.1111/bjh.16221
28. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases
with age. Blood 1999;94(3):909-913. https://doi.org/10.1182/blood.V94.3.909.415k02_909_913
29. Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245
patients. Br J Haematol 2003;122(6):966-974. https://doi.org/10.1046/j.1365-2141.2003.04547.x
30. Steurer M, Quittet P, Papadaki H, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol
2017;98(2):112-120. https://doi.org/10.1111/ejh.12807
31. Palau J, Sancho E, Herrera M, et al. Characteristics and management of primary and other immune
thrombocytopenias: Spanish registry study. Hematology 2017;22(8):484-492. https://doi.org/10.1080/
10245332.2017.1311442
32. Wei Y, Ji X, Wang W, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial. Blood 2016;127(3):296-302. https:// doi.org/10.1182/blood-2015-07-659656
33. Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190-4207. https://doi.org/10.1182/blood-2010-08-302984
34. Gotschalck MA, Norgaard M, Risbo N, et al. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia. Eur J Haematol 2021;107(1):145-156. https://doi.org/10.1111/ejh.13635
35. Phatlhane DV, Zemlin AE, Matsha T, et al. The iron status of a healthy South African adult population. Clin Chim Acta 2016;460:240-245. https://doi.org/10.1016/j.cca.2016.06.019
36. Lawrie D, Coetzee LM, Glencross DK. Iron deficiency anaemia in healthy South African women despite iron fortification. S Afr Med J 2008;98(8):606-607.
37. Soto AF, Ford P, Mastoris J. Thrombocytosis in iron deficiency anemia: What the primary care physician needs to know. Blood 2006;108(11):3723.
38. Huscenot T, Darnige L, Wagner-Ballon O, et al. Iron deficiency, an unusual cause of thrombocytopenia: Results from a multicenter retrospective case-controlled study. Ann Hematol 2019;98(10):2299-2302. https://doi.org/10.1007/s00277-019-03757-0
39. Ayalew GD, Mittal J, Khillan R, Kim M, Braverman A, Sidhu G. Thrombocytopenia in severe anemia of iron deficiency. Blood 2010;116(21):5153. https://doi.org/10.1182/blood.V116.21.5153.5153
40. Alabbood M, Ling M, Ho K. Glucocorticoid-induced diabetes among people without diabetes: A literature review. Pract Diabetes 2018;35(2):63-67. https://doi.org/10.1002/pdi.2164
41. Costello RE, Yimer B, Roads P, Jani M, Dixon WG. Glucocorticoid use is associated with an increased risk of hypertension. Rheumatol 2020;60(1):132-139. https://doi.org/10.1093/rheumatology/keaa209
Downloads
Published
Issue
Section
License
Copyright (c) 2025 D Mapimhidze, J Bailly, K Brown, J Bailey, E Verburgh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
